experimental tumors that also were tested under normoxic conditions. In conclusion, integral in the PRAVO study design was the collection of non-irradiated surrogate tissue for the identification of biomarker of vorinostat activity to reflect the timing of administration and also suggest the mechanism of action of the HDAC inhibitor. This objective was achieved by gene expression array analysis of study patients�� PBMC and as a 181223-80-3 consequence, the identification of genes that from experimental models are known to be implicated in biological processes and pathways governed by HDAC inhibitors. Importantly, all of the identified genes showed rapid and transient induction or repression and therefore, in principle, fulfilled the requirement of being pharmacodynamic biomarkers for this radiosensitizing drug in fractionated radiotherapy. Among the identified candidate genes, MYC repression was found in all patient samples and tested experimental conditions, possibly underscoring the impact of the myc protooncogene in this particular therapeutic setting. The active site of mGPDH faces the 1411977-95-1 mitochondrial intermembrane space, as does its calcium-sensitive EF-hand domain that lowers the Km for glycerol 3-phosphate as physiological levels of free calcium rise. This orientation is thought to allow mGPDH to coordinate cytosolic and mitochondrial metabolism during periods of high activity and, not surprisingly, mGPDH is expressed most highly in tissues with variable energy demands including thermogenic brown fat, type II skeletal muscle fibers, brain, sperm and pancreatic b-cells. Further, mGPDH expression is hormonally regulated to alter tissue activity both during development and in response to environmental challenges. Despite the widespread expression of the enzyme, mGPDH-knockout mice display relatively mild phenotypes beyond weaning. These include decreased body mass and decreased white fat mass. However food intake, non-white fat tissues, and metabolic profiles are normal in these mice. Prior to weaning, viability of mGPDH-null pups is decreased by 50%. Such a dramatic developmental bottleneck raises the possibility that the absence of mGPDH in surviving adults may be successfully compensated for by parallel metabolic pathways. In fact, further roles for mGPDH have
